search
Back to results

Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection

Primary Purpose

Meningioma Atypical, Radiotherapy, Progression-Free Survival

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
radiotherapy
Sponsored by
Second Affiliated Hospital, School of Medicine, Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Meningioma Atypical focused on measuring Meningioma Atypical, radiotherapy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who underwent gross total resection at each center and were diagnosed as atypical meningioma (WHO class II) according to the WHO 2016 diagnostic criteria.
  • Gross total resection was defined as modified Simpson 1-3 and confirmed by postoperative magnetic resonance imaging.

Exclusion Criteria:

  • age less than 18 years old or older than 70 years
  • meningioma recurrence
  • patients had previous radiotherapy
  • multiple meningioma
  • optic nerve sheath meningioma or other extracranial meningioma
  • tumor involving venous sinus
  • ECOG score ≥ 2 points
  • preoperative ASA grade ≥ 3
  • previous or current malignant tumors
  • pregnant or lactating women
  • Patients with Gd-DTPA allergies, spatial claustrophobia or pacemaker implantation that can not be conducted constract-enhanced head magnetic resonance examination
  • patients who were unable to obtain informed consent or refused to participate in the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    control

    treatment

    Arm Description

    Follow-up at several time frames

    Radiotherapy would be carried out. Follow-up at the same time frames as the control arm

    Outcomes

    Primary Outcome Measures

    Progression-free survival
    the length of time during and after medication or treatment during which the disease being treated does not get worse

    Secondary Outcome Measures

    3-year survival rate
    the percentage of people in a study or treatment group still alive for 3 years after diagnosis
    3-year progression-free survival
    3 years during and after medication or treatment during which the disease being treated does not get worse
    5-year survival rate
    the percentage of people in a study or treatment group still alive for 5 years after diagnosis
    10-year progression-free survival
    10 years during and after medication or treatment during which the disease being treated does not get worse
    10-year survival rate
    the percentage of people in a study or treatment group still alive for 10 years after diagnosis
    Disease-specific survival
    the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time. The time period usually begins at the time of diagnosis or at the start of treatment and ends at the time of death. Patients who died from causes other than the disease being studied are not counted in this measurement
    overall survival
    From randomization to death due to any cause

    Full Information

    First Posted
    October 14, 2019
    Last Updated
    October 15, 2019
    Sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    Collaborators
    Sir Run Run Shaw Hospital, Zhejiang Provincial People's Hospital, Ningbo Medical Center Lihuili Hospital, Jinhua Central Hospital, Taizhou Hospital, Shaoxing Hospital of Zhejiang University, People's Hospital of Quzhou, Huizhou Municipal Central Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04127760
    Brief Title
    Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection
    Official Title
    A Multicenter Randomized Controlled Trial of the Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2019
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 1, 2020 (Anticipated)
    Primary Completion Date
    January 1, 2028 (Anticipated)
    Study Completion Date
    January 1, 2033 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    Collaborators
    Sir Run Run Shaw Hospital, Zhejiang Provincial People's Hospital, Ningbo Medical Center Lihuili Hospital, Jinhua Central Hospital, Taizhou Hospital, Shaoxing Hospital of Zhejiang University, People's Hospital of Quzhou, Huizhou Municipal Central Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Postoperative adjuvant radiotherapy is a key component of comprehensive treatment of meningioma. However, for atypical meningioma after total resection, there is still a huge controversy in patients who need adjuvant radiotherapy after surgery. Many scholars have focused on this problem and carried out some small-scale retrospective studies, but they have contradictory results. Some of the studies found that postoperative adjuvant radiotherapy could not improve the prognosis of patients, but was questioned because the sample size was too small, resulting in insignificant results, while other studies found that postoperative adjuvant radiotherapy can improve progression free survival. A study based on the National Cancer Database found that postoperative adjuvant radiotherapy and gross tumor resection are associated with a good prognosis. A recent meta-analysis enrolled a total of 757 patients and found that postoperative adjuvant radiotherapy reduced the risk of tumor recurrence but did not improve survival time. Our team reviewed the meningioma data in the SEER database and conducted a study previously. The study found that postoperative adjuvant radiotherapy did not improve the overall survival of these patients. The relevant research results were recently published in Frontiers in oncology. We further reviewed and summarized the single-center data of our hospital and found that postoperative adjuvant radiotherapy could not improve the progression free survival and overall survival of patients. Besides, we also performed a meta-analysis and found that postoperative adjuvant radiotherapy had a trend to improve progression-free survival, but there was no statistical difference. Because there are many deficiencies in previous researches, and the research results are also contradictory, it is still unclear whether patients with atypical meningioma who have undergone gross total resection can benefit from postoperative adjuvant radiotherapy. Further high quality clinical trials is still needed to be conducted in order to guide the postoperative care of patients. Therefore, we intend to conduct this multicenter randomized controlled trial to determine the value of postoperative adjuvant radiotherapy in patients with atypical meningioma who underwent gross total resection.
    Detailed Description
    The study aims to enroll a total of 140 participants. Subjects would be enrolled with the following information: name, age, gender, contact, KPS score, preoperative ASA score, current ECOG score, tumor location, date of surgery, degree of tumor resection (modified Simpson grade), pathology type, Ki-67 Proliferation index, etc. The preoperative magnetic resonance image of the subject is stored. Tissue specimens are genetically examined. Using a simple randomization method and random assignment in a 1:1 ratio, a random sequence was first generated, and SAS version 9.1 statistical software was used to generate an allocation sequence table including subject numbers, 140 random numbers, and random groupings. 140 Subjects would be assigned to the test group (n=70) and the control group (n=70) in a 1:1 ratio. The table of the assignment sequence is duplicated and saved by the neurosurgical secretary and the trial designer of the Second Affiliated Hospital of Zhejiang University. The secretary puts the group mark into the 140 opaque kraft envelopes with the serial number 1 to 140 according to the order of the allocation sequence table, and submits them to the test designer. Zhige Guo is responsible for enrolling the participants according to the inclusion criteria, assigning the subjects numbers according to the order of the treatment, and Qiang Zeng is responsible for disassembling the corresponding opaque envelopes according to the number of the subjects, and exerting interventions according to the group marks. Chenhan Ling is responsible for follow-up and regular measurement of various indicators, and Fei Dong is responsible for the images reports. Until the end of the trial, Zhige Guo, Chenhan Ling and Fei Dong would not know the grouping of the subjects. The test level of the study was α=0.05, and the two-sided test was used. All statistical analysis was performed by SPSS 16.0 statistical software. For PFS, OS, and DSS data, the COX proportional hazards model was used to calculate the hazard ratio (HR) of radiotherapy and to assess the statistical difference between the corresponding prognostic data between the two groups. For the 3-year progression-free survival, 3-year survival rate, and 5-year progression-free survival, 5-year survival rate data, the chi-square test was used to compare the differences between the two groups.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Meningioma Atypical, Radiotherapy, Progression-Free Survival, Adverse Effect of Radiation Therapy
    Keywords
    Meningioma Atypical, radiotherapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    140 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    control
    Arm Type
    No Intervention
    Arm Description
    Follow-up at several time frames
    Arm Title
    treatment
    Arm Type
    Experimental
    Arm Description
    Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
    Intervention Type
    Radiation
    Intervention Name(s)
    radiotherapy
    Intervention Description
    Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
    Primary Outcome Measure Information:
    Title
    Progression-free survival
    Description
    the length of time during and after medication or treatment during which the disease being treated does not get worse
    Time Frame
    60months
    Secondary Outcome Measure Information:
    Title
    3-year survival rate
    Description
    the percentage of people in a study or treatment group still alive for 3 years after diagnosis
    Time Frame
    36months
    Title
    3-year progression-free survival
    Description
    3 years during and after medication or treatment during which the disease being treated does not get worse
    Time Frame
    36months
    Title
    5-year survival rate
    Description
    the percentage of people in a study or treatment group still alive for 5 years after diagnosis
    Time Frame
    60months
    Title
    10-year progression-free survival
    Description
    10 years during and after medication or treatment during which the disease being treated does not get worse
    Time Frame
    120 months
    Title
    10-year survival rate
    Description
    the percentage of people in a study or treatment group still alive for 10 years after diagnosis
    Time Frame
    120 months
    Title
    Disease-specific survival
    Description
    the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time. The time period usually begins at the time of diagnosis or at the start of treatment and ends at the time of death. Patients who died from causes other than the disease being studied are not counted in this measurement
    Time Frame
    from diagnosis up to 10 years
    Title
    overall survival
    Description
    From randomization to death due to any cause
    Time Frame
    from diagnosis up to 10 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients who underwent gross total resection at each center and were diagnosed as atypical meningioma (WHO class II) according to the WHO 2016 diagnostic criteria. Gross total resection was defined as modified Simpson 1-3 and confirmed by postoperative magnetic resonance imaging. Exclusion Criteria: age less than 18 years old or older than 70 years meningioma recurrence patients had previous radiotherapy multiple meningioma optic nerve sheath meningioma or other extracranial meningioma tumor involving venous sinus ECOG score ≥ 2 points preoperative ASA grade ≥ 3 previous or current malignant tumors pregnant or lactating women Patients with Gd-DTPA allergies, spatial claustrophobia or pacemaker implantation that can not be conducted constract-enhanced head magnetic resonance examination patients who were unable to obtain informed consent or refused to participate in the study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Qiang Zeng, MD
    Phone
    +86 0571 87784715
    Email
    zengqiang@zju.edu.cn
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jianmin Zhang, MD, PhD
    Phone
    +86 0571 87784715
    Email
    zjm135@zju.edu.cn

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection

    We'll reach out to this number within 24 hrs